View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 20, 2020

Covis Pharma studies asthma drug Alvesco for Covid-19

Covis Pharma has launched a Phase III clinical trial to evaluate its asthma drug Alvesco (ciclesonide) for the treatment of non-hospitalised, symptomatic Covid-19 patients aged 12 years and above.

The company, which is based in Luxembourg with operations in Zug, Switzerland, secured the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application of the drug to treat Covid-19.

Designed to assess the drug’s safety and efficacy, the multi-centre, randomised, double-blind, placebo-controlled trial commenced patient enrolment.

Read more here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena